18 Jul Forta Bio
Zoya Gluzman-Poltorak, Ph.D., CEO and Co-Founder
Oct. 8 | 10:00am | FLW Ballroom G
San Francisco, CA
Forta Bio is a novel California-based biotech company developing precision DNA therapies that selectively eliminate disease-driving immune, cancer and other pathogenic cells— without compromising healthy immunity. Our proprietary cell targeting 6-thio-deoxyguanosine oligonucleotides (6tdGO) platform uses a dual mechanism of action to directly disrupt telomeres in specific telomerase positive (TERT+) pathogenic cells while activating the body’s immune response. This approach is uniquely suited for treating aggressive cancers, autoimmune and age-related diseases. We focus on high-burden, underserved conditions — particularly those affecting women and children — and pursue accelerated regulatory pathways. Backed by validated science from City of Hope and led by an experienced team with proven therapeutic development and deal-making track record, Forta Bio is on a mission to bring smarter, safer, and more targeted therapies to patients who need them most.
